View Older Stories View More Recent Stories

Jun 29, 2021 07:07AM Bristol-Myers Squibb (BMY) Receives EC Approval for Opdivo Plus Yervoy for Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemothe
Jun 29, 2021 07:06AM Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastati
Jun 25, 2021 06:59AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Opdivo as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemor
Jun 25, 2021 06:59AM Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following
Jun 25, 2021 06:50AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecm for R/R Multiple Myeloma
Jun 25, 2021 06:50AM Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
Jun 18, 2021 09:35AM Bristol-Myers Squibb (BMY) Receives European Commission Approval for Onureg as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
Jun 18, 2021 09:34AM Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
Jun 17, 2021 06:30PM Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate
Jun 17, 2021 04:16PM Bristol Myers Squibb Announces Dividend
Jun 14, 2021 08:01AM Exelixis (EXEL) Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb (BMY) to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
Jun 14, 2021 08:00AM Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
Jun 11, 2021 06:11AM Bristol-Myers Squibb (BMY), Acceleron (XLRN) Present First Results from Phase 2 BEYOND Study of Reblozyl in Adults with NTD Beta Thalassemia
Jun 11, 2021 03:00AM Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
Jun 10, 2021 04:16PM Bristol Myers Squibb and GRYT Health Evolve Virtual Patient Advocacy Experience
Jun 10, 2021 07:05AM Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021
Jun 10, 2021 07:00AM Bristol-Myers Squibb (BMY) Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractor
Jun 10, 2021 06:59AM Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line
Jun 4, 2021 06:59AM Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference
Jun 3, 2021 05:02PM Bristol-Myers Squibb (BMY) Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival
Jun 3, 2021 05:01PM Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced
Jun 2, 2021 06:59AM Bristol-Myers Squibb (BMY) Receives EC Approval for Opdivo Plus Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
Jun 2, 2021 06:59AM Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases
Jun 2, 2021 06:59AM Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
May 27, 2021 04:15PM Bristol-Myers Squibb (BMY) Announces FDA Approves its Zeposia, an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
May 27, 2021 04:13PM U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis¹
May 26, 2021 06:59AM Bristol Myers Squibb to Take Part in Bernstein’s 37th Annual Strategic Decisions Conference
May 25, 2021 06:59AM Bristol Myers Squibb to Host Virtual Investor Event to Discuss ASCO 2021 Highlights
May 23, 2021 11:35AM Bristol Myers Squibb Presents New Data at Digestive Disease Week® on Zeposia (ozanimod) Highlighting Clinical Benefits and Safety Profile in Patients with Ulcerative Colitis
May 21, 2021 04:17PM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Opdivo plus Yervoy for Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer A
May 21, 2021 04:16PM Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic
May 20, 2021 01:30PM Bristol-Myers Squibb (BMY) Announces FDA Approval for Opdivo as Adjuvant Treatment for GEJ Cancer
May 20, 2021 01:26PM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Ch
May 20, 2021 06:59AM Bristol-Myers Squibb (BMY) Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors
May 20, 2021 06:59AM Bristol Myers Squibb Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors
May 19, 2021 05:00PM Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo (nivolumab) in Patients with Previous
May 19, 2021 05:00PM Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
May 19, 2021 05:00PM Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy Demonstrates Durable Overall Survival vs. Chemotherapy at Two Years in First-Line Non-Small Cell Lung Cancer in Phase 3 Chec
May 19, 2021 05:00PM Four-Year Data from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Non-Small Cell Lung Cancer with PD-L1 Expression ≥
May 19, 2021 05:00PM Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel
May 19, 2021 04:00AM Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb
May 18, 2021 07:31AM Agenus (AGEN) and Bristol Myers Squibb (BMY) Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
May 18, 2021 07:30AM Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
May 18, 2021 07:30AM Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
May 18, 2021 07:30AM Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
May 18, 2021 06:59AM Bristol Myers Squibb to Take Part in UBS Global Healthcare Virtual Conference
May 15, 2021 12:15PM Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy at American College of Cardiology�
May 12, 2021 11:44AM Bristol Myers Squibb (BMY) Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders
May 12, 2021 11:43AM Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders
May 5, 2021 06:59AM Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference
View More Recent Stories View Older Stories